These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 1689620)

  • 1. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
    Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost.
    Nichols WW; Nicolini FA; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):231-6. PubMed ID: 1717784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    Saito T; Saitoh S; Asakura T; Kanke M; Owada K; Maruyama Y
    Int J Cardiol; 1993 Mar; 38(3):225-33. PubMed ID: 8463004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator.
    Mehta JL; Nicolini FA; Nichols WW; Saldeen TG
    J Am Coll Cardiol; 1991 Mar; 17(3):805-11. PubMed ID: 1899681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.
    Kerins DM; Shuh M; Kunitada S; Fitzgerald GA; Fitzgerald DJ
    J Pharmacol Exp Ther; 1991 Apr; 257(1):487-92. PubMed ID: 1708425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
    Topol EJ; Ellis SG; Califf RM; George BS; Stump DC; Bates ER; Nabel EG; Walton JA; Candela RJ; Lee KL
    J Am Coll Cardiol; 1989 Oct; 14(4):877-84. PubMed ID: 2477426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
    Mehta JL; Nichols WW; Saldeen TG; Chandna VK; Nicolini FA; Lawson DL; ter Riet MF
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):112-20. PubMed ID: 1696653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
    Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
    Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ; Prager NA; Sobel BE; Abendschein DR
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
    Rebello SS; Huang J; Saito K; Saucedo JF; Bates ER; Lucchesi BR
    Eur J Pharmacol; 1999 Jun; 374(3):399-410. PubMed ID: 10422784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
    Tomaru T; Uchida Y; Sonoki H; Tsukamoto M; Sugimoto T
    Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.